Semaglutide still the GLP-1 heavyweight If Novo Nordisks semaglutide were counted as a single drug, it would be second bestselling drug of 2023, with total sales of $19.93 billion compared to Keytrudas (pembrolizumab) $25.01 billion
Patients using continuous glucose monitoring or regular capillary blood glucose testing may notice less pronounced glucose spikes after meals and a gradual lowering of overall glucose trends
As frustrating as it sounds, IBS loves to keep things individual
Roussel R, d'Emden MC, Fisher M, et al
Ozempic offers a proven, highly effective way of controlling blood sugar and weight loss, although with higher costs and potential side effects
It enhances blood sugar control by increasing insulin release, reducing liver glucose output, and slowing gastric emptying